The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
Michael S. Rafii(University of Southern California), Paul Aisen(University of Southern California), Robert A. Rissman(University of Southern California), Michael Donohue(Alzheimer’s Disease Neuroimaging Initiative), Shobha Dhadda(Eisai (United States)), Sarah Walter(UC San Diego Health System), Claire Roberts(Beckley Foundation), Rema Raman(University of Southern California), Chad J. Swanson(Eisai (United States)), Jin Zhou(Eisai (United States)), Keith A. Johnson(Brigham and Women's Hospital), David Li(Eisai (United States)), Gopalan Sethuraman(Eli Lilly (United States)), Michael C. Irizarry(Eisai (United States)), Reisa A. Sperling(Harvard University), Lynn D. Kramer(Eisai (United States)), Stephen Krause(Eisai (United States))
Cited by 266
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k